Drug intelligence / Profile preview

ruxolitinib + chidamide

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of ruxolitinib, a selective JAK1/JAK2 inhibitor, and chidamide (tucidinostat), a selective histone deacetylase (HDAC) inhibitor. This combination targets both the JAK-STAT signaling pathway and epigenetic regulation through HDAC inhibition. The combination has shown synergistic anti-tumor effects, particularly in overcoming chidamide resistance in Natural Killer/T-cell Lymphoma (NKTL) and potentially in other hematological malignancies.

Targets

JAK2 (Janus kinase 2)HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on ruxolitinib + chidamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruxolitinib + chidamide.

Explore the full profile